Confluence
One Allegheny Square, Suite 700, Pittsburgh, PA, 15212-5345, United States
Overview
Founded in 1991, Confluence is a global leader in fund administration automation. Confluence helps investment management companies gain unprecedented control by automating every step of the fund administration process including the collection, creation, confirmation, and delivery of investment product data. Results are lower costs, reduced risk, decreased reporting turnaround times, and the scalability to automate more processes without additional resources. Confluence solutions are used by 40 percent of the leading global investment managers, and more than 60 percent of U.S. mutual funds. The Unity platform from Confluence addresses a wide range of problems from performance measurement to customized reporting for a full array of domestic and international managed investment products, including mutual funds, funds of funds, collective funds, separate accounts, and variable products, as well as hedge funds and other alternative investments. Major fund companies such as the Principal Financial Group, T. Rowe Price, and Russell Investments; and service providers such as U.S. Bancorp Fund Services rely on Confluence
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 1
- Active investors
- 8
Sector focus
- Consulting
- Data Center Automation
- Enterprise Software
- Finance
- Information Technology
- Software
Investment portfolio
- Atomic Tessellator
Participated · Seed · Apr 2026
Atomic Tessellator uses a simulation-first platform to compress materials discovery timelines from 3–4 years in a lab to weeks and to reduce lab costs to less than 1% of traditional methods. The company reports arriving at synthesis with high-confidence candidates rather than untested hypotheses and has announced the lab synthesis of Vireon, a rare earth–free magnet that outperforms existing rare-earth alternatives on key metrics. Behind Vireon, Atomic Tessellator says it has a pipeline of around 20 novel material candidates, with a significant number already entering lab synthesis. Founder and CEO Alain Richardt is cited by investors for combining scientific rigour with commercial clarity. The recent $11.3 million seed round led by Crane Venture Partners and participation from IQT, Salus Ventures and others will support further synthesis and commercialisation efforts. No revenue or user metrics were disclosed in the announcement.